Table 1 Characteristics of and medications for RA-ILD
From: Impact of radiological honeycombing in rheumatoid arthritis-associated interstitial lung disease
Non-honeycomb group | Honeycomb group | P value | |
|---|---|---|---|
No. of patients | 24 | 16 | |
Age, years, mean ± SD | 65.3 ± 11.6 | 67.9 ± 7.4 | 0.443 |
Male, N (%) | 8 (33%) | 8 (50%) | 0.339 |
Current or ex-smoker, N (%) | 11 (46%) | 9 (56%) | 0.748 |
Initial CT pattern, N (%) | 0.491 | ||
Probable UIP | 9 (38%) | 5 (31%) | |
Indeterminate; mixed NSIP/UIP | 9 (38%) | 9 (56%) | |
NSIP | 6 (25%) | 2 (13%) | |
CPFE, N (%) | 7 (29%) | 2 (13%) | 0.272 |
Acute exacerbation of ILD during follow-up, N (%) | 4 (17%) | 3 (19%) | > 0.999 |
KL-6, U/mL, mean ± SD | 804.7 ± 525.9 | 1150.1 ± 791.4 | 0.114 |
SP-D, ng/mL, mean ± SD | 144.3 ± 121.0 | 172.2 ± 136.4 | 0.610 |
%FVC, mean ± SD | 84.5 ± 20.2 | 82.8 ± 14.2 | 0.812 |
FEV1/FVC ratio, % mean ± SD | 81.5 ± 7.8 | 86.6 ± 6.8 | 0.122 |
%DLCO, mean ± SD | 67.5 ± 14.8 | 62.2 ± 12.5 | 0.420 |
CPI, mean ± SD | 32.4 ± 12.1 | 41.0 ± 11.3 | 0.138 |
Median follow-up period of CT scans, years (range) | 4.0 (1.1–10.3) | 5.2 (2.9–8.7) | 0.194 |
Median observation follow-up, years (range) | 4.7 (1.4–12.7) | 6.2 (2.8–10.1) | 0.269 |
Deaths (during follow-up), N | 6 (25%) | 7 (44%) | 0.305 |
Cause of death, N | 0.643 | ||
Chronic respiratory failure | 1 | 2 | |
Acute exacerbation | 3 | 1 | |
Malignancy | 1 | 1 | |
Others | 1 | 3 | |
Medications used during follow-up, N | |||
Corticosteroid | 9 | 11 | 0.105 |
Methotrexate | 9 | 3 | 0.297 |
Iguratimod | 3 | 0 | 0.262 |
Calcineurin inhibitor | 9 | 7 | 0.750 |
Biologics | 5 | 2 | 0.681 |
Pirfenidone or nintedanib | 0 | 1 | 0.400 |